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Purpose of the study
To assess metabolic, anthropometric and cardiovascular
risk profile of a cohort undergoing stable nevirapine ther-
apy associated with TDF+FTC (TVD), AZT+3TC (CBV) or
ABC+3TC (KVX).
Methods
Cross-sectional observational study that included all con-
secutive HIV-infected patients seen at a metabolic clinic
undergoing nevirapine therapy for >6 months associated
with TVD, CBV or KVX.
Summary of results
244 patients were included. Table 1.
Rho of Spearman did not find any correlation between
NVP exposure and the surrogate toxicity end-points (all: p
= ns).
Conclusion
KVX arm displayed a greater pro-atherogenic risk profile
notwithstanding lower BMI in respect to CBV and TVD.
This non-randomised cohort cannot discriminate if
patients with a higher underlying risk of cardiovascular
disease might be initially placed on KVX or if KVX associ-
ated with NVP per se, had a poorer metabolic profile com-
pared with the TVD and CBV arms. Careful assessment of
metabolic parameters should be evaluated in people
undergoing the association KVX+NEV even beyond the
initial 6 months of therapy and appropriate lipid-lower-
ing therapy started if needed.
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Table 1: 
Median* or %° Total TVD n = 142 pts CBV n = 62 pts KVX n = 40 pts p-value
Age, (yrs)* 44.0 44.5 42.0 44.0 .173
CDC Group C° 25.8 25.4 18 9 .793
Nadir CD4 (c/μL)* 156 141 166 188 .457
NRTI cum exp (mths)* 119 132 112 126 .073
Current NRTI Tx (mths)* 18.1 12.3 24.9 21.7 <.001
PI cum exp (mths)* 42 47 36 38 .100
NNRTI cum exp (mths)* 45 40 52 55 .038
Current NEV Tx (mths)* 20 13.4 24.9 21.8 .003
BMI 22.5 22.5 23.55 21.54 .020
Waist (cm)* 83 83 87 80 .009
Total fat mass (gr)* 9905 9538 11926 8656 .012
Total lean mass (gr)* 50754 51590 50754 45940 .257
% fat in legs* 9.14 9.10 12.01 7.43 .080
% fat in legs/BMI* 0.40 0.41 0.48 0.35 .239
HOMA 2.79 2.78 2.78 2.82 .993
TG (mg/dL)* 130 120 133 142 .200
TC (mg/dL)* 199 194 196 215 .040
HDL (mg/dL)* 49 49 51 48 .120
LDL (mg/dL)* 123 122 113 137 .028
ApoB (mg/dL)* 102 99 94.5 115.5 .009
ApoA1 (mg/dL)* 151 146 163.5 157 <.001
